News mentioning HNSCC
19 stories
Oct 13, 26BioNTech’s mRNA cancer vaccine fails phase 3 test, significantly denting analysts’ confidence
Sep 8, 26Inhibrx CEO says progression-free survival data leave ‘no question’ about OX40 agonist’s durability
May 11, 26INBRX-106 Plus Pembrolizumab Yields Efficacy Benefit vs Pembrolizumab Alone in First-Line HNSCC
May 8, 26Post–T-DXd Sacituzumab Govitecan Plus Trastuzumab Yields Low ORR in HER2+ Metastatic Breast Cancer
May 8, 26Capivasertib/Fulvestrant Yields Numerical OS Advantage in PIK3CA/AKT1/PTEN–Altered Breast Cancer